RYR1 and congenital myopathy: In order to target these unmet clinical needs we exploited the heterozygous mouse model we created carrying compound heterozygous RyR1 mutations (p.Q1970fsX16 + p.A4329D), for a preclinical study aimed at developing a therapeutic strategy for patients with congenital myopathies.